[
  {
    "column": "S5",
    "description": "S5: For how many years have you practiced in this specialty, post-residency?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S6",
    "description": "S6: What percentage of your professional time is devoted to direct patient care / clinical practice as opposed to teaching, research or administration?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S7a_Hr1c1",
    "description": "S7a_Hr1c1: Acute myeloid leukemia (AML) - In the past 12 months, how many unique patients have you personally actively managed with the following oncologic conditions? For “actively managed” please refer to patients you have seen at least once in the",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_H",
    "context": ""
  },
  {
    "column": "S7a_Hr2c1",
    "description": "S7a_Hr2c1: Acute lymphoblastic leukemia (ALL) - In the past 12 months, how many unique patients have you personally actively managed with the following oncologic conditions? For “actively managed” please refer to patients you have seen at least once i",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_H",
    "context": ""
  },
  {
    "column": "S7a_Hr3c1",
    "description": "S7a_Hr3c1: Prostate cancer - In the past 12 months, how many unique patients have you personally actively managed with the following oncologic conditions? For “actively managed” please refer to patients you have seen at least once in the past 12 month",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_H",
    "context": ""
  },
  {
    "column": "S7a_Hr4c1",
    "description": "S7a_Hr4c1: Multiple myeloma - In the past 12 months, how many unique patients have you personally actively managed with the following oncologic conditions? For “actively managed” please refer to patients you have seen at least once in the past 12 mont",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_H",
    "context": ""
  },
  {
    "column": "S7a_Hr5c1",
    "description": "S7a_Hr5c1: Chronic lymphocytic leukemia (CLL) - In the past 12 months, how many unique patients have you personally actively managed with the following oncologic conditions? For “actively managed” please refer to patients you have seen at least once i",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_H",
    "context": ""
  },
  {
    "column": "S7a_Hr6c1",
    "description": "S7a_Hr6c1: Bladder cancer - In the past 12 months, how many unique patients have you personally actively managed with the following oncologic conditions? For “actively managed” please refer to patients you have seen at least once in the past 12 months",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_H",
    "context": ""
  },
  {
    "column": "S7a_Hr7c1",
    "description": "S7a_Hr7c1: Breast cancer - In the past 12 months, how many unique patients have you personally actively managed with the following oncologic conditions? For “actively managed” please refer to patients you have seen at least once in the past 12 months",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_H",
    "context": ""
  },
  {
    "column": "S7a_Hr8c1",
    "description": "S7a_Hr8c1: Colorectal cancer - In the past 12 months, how many unique patients have you personally actively managed with the following oncologic conditions? For “actively managed” please refer to patients you have seen at least once in the past 12 mon",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_H",
    "context": ""
  },
  {
    "column": "S7a_Ur1c1",
    "description": "S7a_Ur1c1: Prostate cancer - In the past 12 months, how many unique patients have you personally actively managed with the following urology conditions? For “actively managed” please refer to patients you have seen at least once in the past 12 months",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_U",
    "context": ""
  },
  {
    "column": "S7a_Ur2c1",
    "description": "S7a_Ur2c1: Bladder cancer - In the past 12 months, how many unique patients have you personally actively managed with the following urology conditions? For “actively managed” please refer to patients you have seen at least once in the past 12 months f",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_U",
    "context": ""
  },
  {
    "column": "S7a_Ur3c1",
    "description": "S7a_Ur3c1: Testicular cancer - In the past 12 months, how many unique patients have you personally actively managed with the following urology conditions? For “actively managed” please refer to patients you have seen at least once in the past 12 month",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_U",
    "context": ""
  },
  {
    "column": "S7a_Ur4c1",
    "description": "S7a_Ur4c1: Kidney cancer - In the past 12 months, how many unique patients have you personally actively managed with the following urology conditions? For “actively managed” please refer to patients you have seen at least once in the past 12 months fo",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S7a_U",
    "context": ""
  },
  {
    "column": "S7_B",
    "description": "S7_B: Of your [pipe:hS7_B] prostate cancer patients, how many were actively managed for non-curative prostate cancer in the past 12 months? Non-curative prostate cancer patients are those that have progressed after receiving definitive therapy (e.g., radi",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S7_C",
    "description": "S7_C: Of your [pipe:hS7_C] bladder cancer patients actively managed in the past 12 months, how many were locally advanced or metastatic? Include patients you treat currently AND patients you referred to clinical trial in the last 12 months AND your patien",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "S9r1c1",
    "description": "S9r1c1: Primary Care, Internal Medicine, General Practice or Family Practice - Approximately, how many physicians of each of the following specialties are currently on staff in your practice? If your practice has multiple locations, please consider your p",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S9",
    "context": ""
  },
  {
    "column": "S9r2c1",
    "description": "S9r2c1: Hematologist - Approximately, how many physicians of each of the following specialties are currently on staff in your practice? If your practice has multiple locations, please consider your primary location.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S9",
    "context": ""
  },
  {
    "column": "S9r3c1",
    "description": "S9r3c1: Hematologist-Oncologist - Approximately, how many physicians of each of the following specialties are currently on staff in your practice? If your practice has multiple locations, please consider your primary location.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S9",
    "context": ""
  },
  {
    "column": "S9r4c1",
    "description": "S9r4c1: Medical Oncologist - Approximately, how many physicians of each of the following specialties are currently on staff in your practice? If your practice has multiple locations, please consider your primary location.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S9",
    "context": ""
  },
  {
    "column": "S9r5c1",
    "description": "S9r5c1: Gastroenterologist - Approximately, how many physicians of each of the following specialties are currently on staff in your practice? If your practice has multiple locations, please consider your primary location.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S9",
    "context": ""
  },
  {
    "column": "S9r6c1",
    "description": "S9r6c1: Urologist - Approximately, how many physicians of each of the following specialties are currently on staff in your practice? If your practice has multiple locations, please consider your primary location.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S9",
    "context": ""
  },
  {
    "column": "S9r7c1",
    "description": "S9r7c1: Radiation Oncologist - Approximately, how many physicians of each of the following specialties are currently on staff in your practice? If your practice has multiple locations, please consider your primary location.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S9",
    "context": ""
  },
  {
    "column": "S9r8c1",
    "description": "S9r8c1: Urological Oncologist - Approximately, how many physicians of each of the following specialties are currently on staff in your practice? If your practice has multiple locations, please consider your primary location.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S9",
    "context": ""
  },
  {
    "column": "S9r9c1",
    "description": "S9r9c1: Other (please specify): - Approximately, how many physicians of each of the following specialties are currently on staff in your practice? If your practice has multiple locations, please consider your primary location.",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "S9",
    "context": ""
  },
  {
    "column": "Q1c1r1",
    "description": "Q1c1r1: Astellas - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology dr",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r2",
    "description": "Q1c1r2: EMD Serono - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r3",
    "description": "Q1c1r3: Bristol-Myers Squibb (BMS) - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company rela",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r4",
    "description": "Q1c1r4: Genentech - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology d",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r5",
    "description": "Q1c1r5: Pfizer - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology drug",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r6",
    "description": "Q1c1r6: Janssen / Johnson & Johnson - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company rel",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r7",
    "description": "Q1c1r7: Bayer - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology drugs",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r8",
    "description": "Q1c1r8: Abbvie - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology drug",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r11",
    "description": "Q1c1r11: Novartis - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology d",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r12",
    "description": "Q1c1r12: Daiichi-Sankyo - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to onco",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r13",
    "description": "Q1c1r13: Amgen - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology drug",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r14",
    "description": "Q1c1r14: Seagen (Seattle Genetics) - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company rela",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r15",
    "description": "Q1c1r15: GSK - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology drugs",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r16",
    "description": "Q1c1r16: AstraZeneca - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncolog",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r17",
    "description": "Q1c1r17: Gilead - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology dru",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q1c1r18",
    "description": "Q1c1r18: Merck - You indicated that you have interacted with the following companies in the past 6 months: [pipe:hS12XS12aCompetitors]. For each of these companies, approximately how many times have you interacted with the company related to oncology drug",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q1c1",
    "context": ""
  },
  {
    "column": "Q11r1",
    "description": "Q11r1: The rep shows me print materials - Please rank order the following approaches, based on how you prefer to receive information from pharmaceutical representatives, during your in-person meetings with the reps. Click to rank 1 for your most preferred",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q11",
    "context": ""
  },
  {
    "column": "Q11r2",
    "description": "Q11r2: The rep shows me the information on his/her iPad - Please rank order the following approaches, based on how you prefer to receive information from pharmaceutical representatives, during your in-person meetings with the reps. Click to rank 1 for you",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q11",
    "context": ""
  },
  {
    "column": "Q11r3",
    "description": "Q11r3: I use my phone/iPad to scan a QR Code and receive the information on my device - Please rank order the following approaches, based on how you prefer to receive information from pharmaceutical representatives, during your in-person meetings with the",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q11",
    "context": ""
  },
  {
    "column": "Q11r4",
    "description": "Q11r4: The rep airdrops the information to my device - Please rank order the following approaches, based on how you prefer to receive information from pharmaceutical representatives, during your in-person meetings with the reps. Click to rank 1 for your m",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q11",
    "context": ""
  },
  {
    "column": "Q11r5",
    "description": "Q11r5: The rep emails the information to me, for me to review on my computer - Please rank order the following approaches, based on how you prefer to receive information from pharmaceutical representatives, during your in-person meetings with the reps. Cl",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q11",
    "context": ""
  },
  {
    "column": "Q11r6",
    "description": "Q11r6: The rep presents the information via a projector - Please rank order the following approaches, based on how you prefer to receive information from pharmaceutical representatives, during your in-person meetings with the reps. Click to rank 1 for you",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q11",
    "context": ""
  },
  {
    "column": "S6a",
    "description": "S6a: What percentage of your professional time is devoted to patient education?",
    "level": "parent",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "NA",
    "context": ""
  },
  {
    "column": "Q16r8c1",
    "description": "Q16r8c1: Commercial prescription coverage (employer-sponsored or self-insured) - For oral oncology drugs specifically, what is the insurance distribution of your oncology patients at your primary practice setting/organization? Please estimate to the best",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q16",
    "context": ""
  },
  {
    "column": "Q16r9c1",
    "description": "Q16r9c1: Medicaid (Medi-Cal for California residents) prescription coverage - For oral oncology drugs specifically, what is the insurance distribution of your oncology patients at your primary practice setting/organization? Please estimate to the best of",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q16",
    "context": ""
  },
  {
    "column": "Q16r10c1",
    "description": "Q16r10c1: Medicare Part C / Medicare Advantage - For oral oncology drugs specifically, what is the insurance distribution of your oncology patients at your primary practice setting/organization? Please estimate to the best of your ability. The sum of your",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q16",
    "context": ""
  },
  {
    "column": "Q16r11c1",
    "description": "Q16r11c1: Medicare Part D without supplemental insurance - For oral oncology drugs specifically, what is the insurance distribution of your oncology patients at your primary practice setting/organization? Please estimate to the best of your ability. The s",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q16",
    "context": ""
  },
  {
    "column": "Q16r12c1",
    "description": "Q16r12c1: Medicare Part D with Supplemental (Medigap) prescription coverage - For oral oncology drugs specifically, what is the insurance distribution of your oncology patients at your primary practice setting/organization? Please estimate to the best of",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q16",
    "context": ""
  },
  {
    "column": "Q16r13c1",
    "description": "Q16r13c1: Veterans Administration (VA), TRICARE, or military prescription coverage - For oral oncology drugs specifically, what is the insurance distribution of your oncology patients at your primary practice setting/organization? Please estimate to the b",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q16",
    "context": ""
  },
  {
    "column": "Q16r14c1",
    "description": "Q16r14c1: Other (please specify): - For oral oncology drugs specifically, what is the insurance distribution of your oncology patients at your primary practice setting/organization? Please estimate to the best of your ability. The sum of your answers must",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q16",
    "context": ""
  },
  {
    "column": "Q16r15c1",
    "description": "Q16r15c1: No prescription drug coverage - For oral oncology drugs specifically, what is the insurance distribution of your oncology patients at your primary practice setting/organization? Please estimate to the best of your ability. The sum of your answer",
    "level": "sub",
    "valueType": "",
    "answerOptions": "NA",
    "parentQuestion": "Q16",
    "context": ""
  }
]